Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline, Vir Biotechnology to Supply Covid-19 Treatment to European Commission

07/28/2021 | 05:05am EDT

By Chris Wack

GlaxoSmithKline PLC and Vir Biotechnology Inc. said they have signed a joint procurement agreement with the European Commission to supply up to 220,000 doses of Covid-19 treatment sotrovimab.

The companies said sotrovimab is an investigational single-dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with Covid-19 who don't require oxygen supplementation and who are at risk of progressing to severe Covid-19.

The agreement enables participating European Union member states to quickly purchase sotrovimab, following local emergency authorization or authorization at the EU level, to treat high-risk patients with Covid-19 who may benefit from early treatment with the medication, the companies said.

Sotrovimab is included in the European Commission's portfolio of promising candidate therapies as part of its Covid-19 Therapeutics Strategy.

Glaxo and Vir have secured supply agreements with a number of governments around the world and will continue those efforts as the pandemic continues to evolve, the companies said. In May, sotrovimab was granted emergency-use authorization by the U.S. Food and Drug Administration for the treatment of mild-to-moderate Covid-19 in high-risk patients. Glaxo and Vir plan to submit a biologics license application to the U.S. FDA in the second half of 2021.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

07-28-21 0705ET

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -1.61% 1391.2 Delayed Quote.5.37%
VIR BIOTECHNOLOGY, INC. 1.59% 45.53 Delayed Quote.66.88%
All news about GLAXOSMITHKLINE PLC
06:36aGLAXOSMITHKLINE : UBS sticks Neutral
MD
02:10aGLAXOSMITHKLINE : Federal Circuit Vacates Judgment, Reinstates Jury's Verdict Of Induced I..
AQ
09/23GLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
09/23Activist Bluebell Capital Takes Small Stake in GSK to Push for Board Change -FT
DJ
09/23GLAXOSMITHKLINE : Survey Shows More People In Favor Of Vaccinations After COVID-19
MT
09/22GLAXOSMITHKLINE : CEO Faces Additional Pressure as Bluebell Joins Elliott in Demanding Man..
MT
09/22GLAXOSMITHKLINE : Activist investor Bluebell takes stake in GSK to challenge chief exec
AQ
09/22Bluebell Capital Takes Stake in GlaxoSmithKline to Shake-up the Company’s Leadership
CI
09/22GLAXOSMITHKLINE : Bluebell Capital Says Believes GSK Should Address Leadership For ôNew GS..
RE
09/22Bluebell capital says believes gsk's emma walmsley would have been a very credible cand..
RE
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2021 33 307 M 45 514 M 45 514 M
Net income 2021 3 857 M 5 271 M 5 271 M
Net Debt 2021 20 885 M 28 541 M 28 541 M
P/E ratio 2021 18,5x
Yield 2021 5,66%
Capitalization 70 770 M 97 195 M 96 709 M
EV / Sales 2021 2,75x
EV / Sales 2022 2,57x
Nbr of Employees 94 066
Free-Float 92,2%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 1 414,00 GBX
Average target price 1 604,94 GBX
Spread / Average Target 13,5%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC5.37%97 195
JOHNSON & JOHNSON4.75%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.19.40%247 760
NOVO NORDISK A/S51.58%233 750
ELI LILLY AND COMPANY37.51%210 490